What Researchers Did
This prospective observational cohort study compared the effects of hyperbaric oxygen therapy versus mirabegron treatment on bladder symptoms in female patients with overactive bladder.
What They Found
Both hyperbaric oxygen therapy (Group 1, n=31) and mirabegron treatment (Group 2, n=44) significantly improved symptom and quality of life scores from baseline. For Group 1, mean changes in ICIQ-SF, OAB-V8, and IIQ-7 scores were 4.12, -10.70, and -4.51 respectively, while for Group 2, they were -4.31, -11.22, and -3.68. No significant differences were observed between the two groups in these score changes (p=0.81, 0.73, and 0.19).
What This Means for Canadian Patients
Female patients in Canada with overactive bladder might consider hyperbaric oxygen therapy as a potential treatment option, as it showed comparable efficacy to mirabegron in improving symptoms and quality of life. This could offer an alternative for those who do not respond well to or cannot tolerate standard pharmacological treatments.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian participants or researchers.
Study Limitations
The study's observational design and relatively small sample size limit the generalizability and strength of its conclusions.